Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, tadalafil (Cialis®) cannot be endorsed for use within NHS Wales for the treatment of the signs and symptoms of benign prostatic hyperplasia in adult males. |
||
|
||
Medicine details |
||
| Medicine name | tadalafil (Cialis®) | |
| Formulation | 5 mg film-coated tablet | |
| Reference number | 618 | |
| Indication | For the treatment of the signs and symptoms of benign prostatic hyperplasia in adult males. |
|
| Company | Eli Lilly & Co Ltd | |
| BNF chapter | Endocrine system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 18/03/2013 | |
| Date of issue | 22/03/2013 | |